Dr. Maja Stojiljkovic, Leader of the Rare Disease Research and Therapeutics Development Group in IMGGE, was awarded Science Fund's project within the program PRIZMA. The GlucoAdjust project develops a novel concept for the treatment of glycogen storage disease Ib and diabetes mellitus type 2 based on glucose level adjustment through binding glucose-6-phospate translocase.